[1]FERLAY J, SHIN HR, BRAY F, et al.Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J].Int J Cancer, 2010, 127:2893-2917.
|
[2]LI Y, CHENG P.Advances in treatment of advanced hepatocellular cancer[J].J Clin Hepatol, 2014, 30 (3) :1001-5256. (in Chinese) 李焱, 程鹏, 中晚期肝癌临床治疗进展[J].临床肝胆病杂志, 2014, 30 (3) :1001-5256.
|
[3]ZHANG WJ, LU SY.Advances in molecularly targeted therapy of hepatocellular carcinoma[J].World Chin J Dig, 2011, 19 (4) :331-337. (in Chinese) 张文杰, 禄韶英.肝细胞癌的分子靶向治疗[J].世界华人消化杂志, 2011, 19 (4) :331-337.
|
[4]WU MC.Current development on surgical treatment of liver cancer[J].Chin J Bases Clin Gen Surg, 2006, 13 (2) :125-128. (in Chinese) 吴孟超.肝癌外科治疗的近期进展[J].中国普外基础与临床杂志, 2006, 13 (2) :125-128.
|
[5]QIN SK, GONG XL.Progress on treatment of sorafenib on hepatocellular carcinoma[J].Chin Clin Oncol, 2008, 13 (12) :1057-1068. (in Chinese) 秦淑逵, 龚新雷.索拉非尼治疗原发性肝癌的研究进展[J].临床肿瘤学杂志, 2008, 13 (12) :1057-1068.
|
[6]STEFANIUK P, CIANCIARA J, WIERCINSKA-DRAPALO A.Present and future possibilities for early diagnosis of hepatocellular carcinoma[J].World J Gastroenterol, 2010, 16 (4) :418-424.
|
[7]ZHANG N, GU J, YIN L, et al.Incorporation of alpha-fetoprotein (AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database[J].Oncotarget, 2016, 7 (49) :81389-81401.
|